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The omentum is enriched with pro-inflammatory effector memory CD8+ T cells in
patients with the obesity-associated malignancy, esophagogastric adenocarcinoma
(EAC) and we have identified the chemokine macrophage inflammatory protein-1alpha
as a key player in their active migration to this inflamed tissue. More recently, others
have established that subsets of memory CD8+ T cells can be classified based on their
surface expression of CX3CR1; the specific receptor for the inflammatory chemokine
fractalkine. CD8+ T cells expressing intermediate levels (CX3CR1INT) are defined as
peripheral memory, those expressing the highest levels (CX3CR1HI) are effector memory/
terminally differentiated and those lacking CX3CR1 (CX3CR1NEG) are classified as central
memory. To date, the fractalkine:CX3CR1 axis has not been examined in the context of
CD8+ T cell enrichment in the omentum and here we examine this chemokines involvement in the accumulation of memory CD8+ T cells in the omentum of EAC patients.
Our data show that fractalkine is significantly enriched in the omentum of EAC patients
and drives migration of T cells derived from EAC patient blood. Furthermore, CX3CR1
is endocytosed specifically by CD8+ T cells upon encountering fractalkine, which is
consistent with the significantly diminished frequencies of CX3CR1INT and CX3CR1HI
CD8+ T cells in the fractalkine-rich environment of omentum in EAC, relative to matched
blood. Fractalkine-mediated endocytosis of CX3CR1 by CD8+ T cells is sustained and
is followed by enhanced surface expression of L-selectin (CD62L). These novel data
align with our findings that circulating CX3CR1NEG CD8+ T cells express higher levels
of L-selectin than CX3CR1INT CD8+ T cells. This is consistent with previous reports and
implicates fractalkine in the conversion of CX3CR1INT CD8+ T cells to a CX3CR1NEG phenotype characterized by alterations in the migratory capacity of these T cells. For the first
time, these findings identify fractalkine as a driver of T cell migration to the omentum in
EAC and indicate that CD8+ T cells undergo sequenced fractalkine-mediated alterations
in CX3CR1 and L-selectin expression. These data implicate fractalkine as more than a
chemotactic cytokine in obesity-associated meta-inflammation and reveal a role for this
chemokine in the maintenance of the CX3CR1NEG CD8+ T cell populations.
Keywords: fractalkine, CX3CR1, T cells, obesity, upper gastrointestinal cancer, inflammation, adhesion, omentum
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INTRODUCTION

at a time when the global obesity problem has reached epidemic
proportions and shows no signs of abating (www.who.int).
For the first time, this study identifies a role for fractalkine
in the recruitment of T cells to the inflamed omentum of EAC
patients implicating this chemokine as a player and potential
therapeutic target in pathological T cell-mediated inflammation
in obesity and obesity-associated malignancies. Importantly, our
data also reveal fractalkine-mediated regulation of CX3CR1 and
L-selectin expression by CD8+ T cells, placing this inflammatory
chemokine as an orchestrator of cytotoxic T cell trafficking and
memory in EAC. The data generated here has ramifications for
fractalkine as a therapeutic target for inflammation particularly
in the context of cancer indicating that antagonism of this pathway might have consequences for L-selectin-dependent cytotoxic
T cell homing to lymph nodes and anti-tumor immunity.

The flexibility and multifaceted functionality of chemokines
together with their involvement in multiple inflammatory
diseases has ignited an interest in their potential as targets
for immunotherapy (1, 2). Indeed, there has been a paradigm
shift in the classification of chemokines as solely chemotactic
cytokines and emerging evidence has uncovered their additional
functions in the generation of effector and memory T cells and
the co-stimulation of cytokine secretion by T cells (3–5). Most
recently, the specific receptor for the inflammatory chemokine
fractalkine, CX3CR1 has been used to classify memory CD8+
T cell subsets (5).
Fractalkine (CX3CL1) exists in both a soluble and transmembrane form, and plays a role in both immune cell migration and
adhesion and has been implicated in multiple inflammatory
diseases such as asthma, dermatitis, diabetes, and neuropathic
pain (6–12). The involvement of this chemokine in several
inflammatory disorders is facilitated through its induction by
inflammatory cytokines such as TNF-α, IFN-γ, and IL-1 (13). In
the context of obesity, fractalkine has already been implicated in
obesity-associated diseases such as diabetes and cardiovascular
disease and in the chronic inflammation that precedes metabolic
dysfunction; meta-inflammation (7, 8, 10, 14). Fractalkine is
known to be expressed by endothelial cells and facilitates vascular
recruitment and adhesion of macrophages, NK cells, and T cells,
however, its expression by both the stromal vascular fraction
(SVF) and the adipocyte fraction has been demonstrated in the
adipose tissue (8). Most studies have focused on the role of fractalkine in macrophage-mediated adipose tissue inflammation (8,
15, 16), with previous work demonstrating a role for fractalkine
in macrophage recruitment and macrophage-adipocyte adhesion
in adipose tissue but, to our knowledge there are no reports of
fractalkine-driven migration of T cells in obesity (8).
The omentum forms the largest component of the visceral adipose tissue (VAT) compartment and is enriched with leukocyte
aggregates which liken it to the follicles of secondary lymphoid
tissues and promote immune responses and inflammation (17).
We have previously shown that the omentum is a hot bed of
T cell-mediated inflammation in patients with esophagogastric
adenocarcinoma (EAC), a malignancy that arises in a background of inflammation and importantly has one of the strongest
associations with obesity of all malignancies (18). Furthermore,
we have identified the macrophage inflammatory protein-1alpha
(MIP-1α)/CCR1 axis as a key pathway governing T cell migration
to the omentum of EAC patients and reported its therapeutic
potential in the space of obesity-associated inflammation (19).
However, the fractalkine pathway may present a more attractive
and more specific therapeutic target in this setting as there is only
one known receptor for this chemokine (CX3CR1), in contrast
to the redundancy observed in other chemokine pathways (1, 20,
21). We have already demonstrated that the omentum of EAC
patients is primed for fractalkine-mediated inflammation through
an abundance of TNF-α-producing CD8+ and CD4+ T cells and
secreted IL-1β and here, we address the role of fractalkine in
inflammatory and cytotoxic T cell trafficking and retention in this
inflamed tissue (22, 23). These questions are extremely relevant
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MATERIALS AND METHODS
Subjects

Forty-seven consecutive consenting patients with EAC, attending the National Esophageal and Gastric Center at St. James’s
Hospital, Dublin from 2011 to 2018 were enrolled in this study.
The patient cohort was similar in age and ethnicity, and 81% had
received neoadjuvant chemo-radiotherapy. The patient group
included 37 males and 10 females, representative of the male predominance in EAC, with an average age of 65.9 years. The mean
BMI at time of surgery was 26.4 and CT-defined visceral fat area
(VFA) was 126.54 cm2 (Table 1). Control blood and omentum
were taken from a group of non-cancer control patients attending
St. James’s Hospital, Dublin for laparoscopic cholecystectomy. All

TABLE 1 | Demographic data.
Age (range years)
Sex ratio (M:F)
Esophageal adenocarcinoma
Gastric adenocarcinoma
Tumor stagea
T0
T1
T2
T3
T4
Nodal statusa
Positive
Negative
Mean BMI (kg/m2) (range)b
Underweight (BMI < 19.9)
Normal weight (BMI 20–24.9)
Overweight (BMI 25–29.9)
Obese (BMI > 30)
Mean waist circumference (cm) (range)
Centrally obese by waist circumferencec
Mean visceral fat area (VFA) (cm2) (range)
Viscerally obese by VFAd
Received Neoadjuvant CRT

65.9 (35–93)
37:10
38
9
4
11
8
20
1
21
23
26.4 (17.8–36.4)
4
12
13
14
93.8 (68–115)
57.75%
126.54 (4.65–353.05)
30%
81%

Tumor stage and nodal status was not available for three patients.
BMI was not available for four patients.
c
Obese waist circumference ≥94 cm for men and ≥80 cm for women (25).
d
Obese VFA >160 cm2 for men and >80 cm2 for women (24).
a

b

2
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cancer patients were evaluated by a dietician. Body mass index,
waist circumference, and anthropometric variables were measured as described previously (23). VFA was assessed by computer
tomography as previously described, with more than 160 and
80 cm2 defining visceral obesity in males and females, respectively
(24). Serum C-reactive protein (CRP) levels were determined as
part of routine testing at time of surgery. Metabolic syndrome was
measured as per the IDF definition (25).

concentration in EAC ACM) or ACM derived from four obese and
three non-obese EAC patients or ACM derived from two obese and
three non-obese non-cancer controls. The assay was incubated for
2 h at 37°C before removal of the insert. The media in the bottom
chambers were taken and centrifuged at 1,300 RPM for 3 min and
then stained for CD3 expression. CountBright Absolute Counting
Beads (Invitrogen) were used to enumerate the absolute number of
CD3+ T cells that had migrated.

Ethics Approval Statement

Quantification of CX3CR1 Expressing
T Cells in Blood and Omentum and
Phenotyping of CX3CR1NEG and CX3CR1INT
CD8+ T Cell Populations

The work was performed in accordance with The Code of Ethics
of the World Medical Association (Declaration of Helsinki) for
experiments involving humans. Patients provided informed
consent for sample and data acquisition and the study received
full ethical approval from the St. James’s Hospital Ethics Review
Board. Patient samples were pseudonymized to protect the privacy rights of the patients.

Freshly isolated PBMC and SVF were stained with monoclonal
antibodies specific for human surface markers; PE-efluor-labeled
CD3 and APC-eFluor780-labeled CD27 (eBioscience, Hatfield,
UK), PE-Cy5.5-labeled CD4, APC-labeled ICAM-1 (CD54),
V500-labeled CD45RA, and BV421-labeled CD8 (BD Biosciences,
Oxford, UK), PE-Cy5-labeled L-selectin (Abcam, Cambridge,
UK), and PE-labeled CX3CR1 (Miltenyi Biotec, Germany).
Cells were acquired using CyAn ADP flow cytometer (Beckman
Coulter) and analyzed with FlowJo software (TreeStar Inc.).

Sample Preparation

Peripheral blood mononuclear cells (PBMC) were isolated by
density centrifugation using Ficoll-Paque™ Plus (GE Healthcare,
Uppsala, Sweden). Omental samples (10 g from each patient) were
digested enzymatically to obtain SVF as previously described (22,
23). Adipose tissue conditioned media (ACM) was prepared as
previously described (22).

CX3CR1 Surface Expression by T Cells
Following Recombinant Fractalkine
Treatment

Quantification of Soluble Fractalkine and
CX3CR1 Levels in Serum and Omentum

To examine the effects of fractalkine on CX3CR1 expression by
CD8+ T cells, PBMC from 17 EAC patients were seeded in RPMI
media at 1 × 106 cells/ml and treated with M199 media or 30 ng/
ml of recombinant fractalkine for 15 min, 30 min, 1 h, 2 h, and 24 h
and subsequently analyzed for CX3CR1 surface expression using
flow cytometry, as described above. To test whether CX3CR1 was
endocytosed, PBMC from 10 EAC patients were treated with M199
media (untreated) or 30 ng/ml of recombinant fractalkine for 2 h
at 4°C (cold treatment) or in the presence of 80 µM of the GTPase
inhibitor dynasore (Sigma Aldrich). To examine whether CX3CR1
is recycled to the surface of CD8+ T cells following fractalkine
treatment, PBMC from three donors were seeded in RPMI media
at 1 × 106 cells/ml and treated with M199 media alone or 30 ng/ml
of recombinant fractalkine for 2 h. Following 2 h, cells were washed
and placed in fractalkine-free media for 24 and 48 h or placed in
fractalkine-free media supplemented with 50 ng/ml of TNF-α or
100 ng/ml of IFN-γ, IL-6, IL-7, IL-17, IL-18, IL-15, or IL-36 or
50 U/ml of IL-2 for 24 h and subsequently analyzed for CX3CR1
surface expression using flow cytometry.

The V-PLEX™ Fractalkine plate (Meso Scale Discovery) was
used to detect the levels of fractalkine in the serum and ACM
of 19 EAC patients according to the manufacturer’s instructions
and read using an MSD Sector S600. The Human CX3CR1 ELISA
Kit (ELISA Genie) was used to measure secreted CX3CR1 in the
serum and ACM of 10 EAC patients and read using a VersaMax™
ELISA microplate reader.

Examining Secreted Adhesion Molecule
Levels in the Omentum of EAC Patients

The Evidence Investigator Adhesion Molecules Array (RANDOX)
was used to detect the concentrations of VCAM-1, ICAM-1,
L-selectin, P-selectin, and E-selectin in the ACM of five EAC
patients according to the manufacturer’s instructions and read
using a RANDOX Evidence Investigator.

T Cell Chemotaxis Assays

To activate the T cells for chemotaxis, PBMC were prepared from
the blood of five EAC patients and three non-cancer controls, and
incubated with CD3/CD28 T-cell expander Dynabeads (Invitrogen)
at a bead:cell ratio of 1:1. Following activation, the beads were
removed and the T cells were counted and resuspended at densities of 2 × 106 cells/ml serum-free RPMI media. Chemotaxis was
assessed using a 5-µm pore transwell filter system (Corning Inc.,
USA). Cells were added to the top chamber in a volume of 100 µl
RPMI, while the bottom chamber contained 600 µl of the following;
M199 media alone (negative control) or M199 media supplemented
with fractalkine at a concentration of 30 ng/ml (based on the mean

Frontiers in Immunology | www.frontiersin.org

Examining CX3CR1 Protein Expression
Following Treatment With Recombinant
Fractalkine

CD8+ T cells from three healthy control subjects were isolated
from PBMC using the EasySep™ Human CD8+ T Cell Isolation
Kit (Stemcell Technologies) and subsequently seeded at a density
of 1 × 106 cells/ml RPMI media and treated with 30 ng/ml of
fractalkine for 24 and 48 h. Flow cytometry was used to confirm
reduction of CX3CR1 surface expression on a subset of treated

3
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FIGURE 1 | Both soluble fractalkine and CX3CR1 are secreted in abundance in the omentum of esophagogastric adenocarcinoma (EAC) patients and fractalkine
can drive migration of EAC patient-derived T cells. (A) Scatter plots showing the fractalkine (top) and soluble CX3CR1 levels (bottom) in paired samples of serum
and adipose tissue conditioned media (ACM) from 10 to 19 EAC patients. (B) Bar charts showing significant fold change migration of peripheral blood-derived
T cells from five EAC patients to M199 media supplemented with 30 ng/ml of recombinant fractalkine, relative to M199 alone negative control. (C) Bar charts
showing the levels of soluble VCAM-1, ICAM-1, E-selectin, P-selectin, and L-selectin in omental adipose tissue conditioned media (ACM) from five EAC patients. (D)
Bar charts showing the fractalkine levels in serum and ACM from 3 non-cancer control subjects and 20 EAC patients, from 9 non-obese and 11 obese EAC
patients, and 17 EAC patients with serum C-reactive protein (CRP) <5 mg/l (low CRP) and 3 EAC patients with serum CRP >5 mg/l (high CRP). (E) Bar charts
showing significant fold change migration of peripheral blood-derived T cells to ACM from three non-obese and four obese EAC patients and three non-obese and
two obese non-cancer controls. *p < 0.05, **p < 0.01, ***p < 0.001 by paired, unpaired t tests and one-way ANOVA with Tukey post hoc analysis.
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and untreated cells after 24 h and the remainder of the cells were
lysed. Protein was extracted using a 6 M urea lysis buffer (15 min
on ice). Protein was quantified against a standard curve using the
Pierce BCA Protein Assay Kit (Thermofisher). Protein (60 µg per
sample) was loaded onto a 10% SDS page gel and electrophoresed
for 80 min. Separated protein was subsequently transferred to a
PVDF membrane. Membrane was blocked in 0.5% Bovine Serum
Albumin (in TBST) for 1.5 h at room temperature. The membrane
was incubated for 1.5 h at room temperature with mouse antihuman CX3CR1 antibody (H-70) (Santa Cruz) at 1:1,000 dilution
in 0.5% BSA TBST. The membrane was incubated for 1 h at room
temperature with secondary antibody (goat anti-mouse IgG-HRP
at 1:5,000 dilution in 0.5% BSA TBST). Bands were visualized using
the West Pico chemiluminescent substrate on a gel doc. Beta-actin
primary mouse anti-human at 1:10,000 dilution (Santa Cruz) was
used as a loading control. Protein extract quality was confirmed
visually via coomassie blue staining (10% gel, 20 µg protein per
sample). CD8+ T cells from three control subjects were isolated
from PBMC using the EasySep™ Human CD8+ T Cell Isolation Kit
(Stemcell Technologies) and subsequently seeded in RPMI media
at 1 × 106 cells/ml and treated with 30 ng/ml of fractalkine for 24
and 48 h. Cell supernatant was collected after 24 and 48 h and the
Human CX3CR1 ELISA Kit (ELISA Genie) was used to compare
secreted CX3CR1 in the untreated and fractalkine-treated cells.

(ACM) of 19 EAC patients revealing that levels of this chemokine
were significantly higher in ACM (mean: 23.66 ng/ml) compared
to serum (mean: 10.56 ng/ml) (p < 0.001, Figure 1A). Soluble
CX3CR1 ELISA revealed that the soluble form of the fractalkine
receptor was also significantly abundant in the ACM of 10 EAC
patients, compared to matched serum suggesting that the fractalkine receptor can be shed in the omental microenvironment
(mean: 18.1 versus 9.3 ng/ml, p < 0.01, Figure 1A). To confirm
whether T cells respond and migrate toward fractalkine-elicited
chemotactic signals in EAC, patient-derived T cell chemotaxis
to 30 ng/ml of fractalkine was measured using a transwell system. Significantly higher fold-levels of T cell migration toward
recombinant fractalkine, compared to serum-free M199 media
were observed supporting our hypothesis of fractalkine-driven
T cell migration to omentum in EAC (M199 versus fractalkine
fold change: 1 versus 2.456, p < 0.05, Figure 1B). An adhesion
molecule array was used to screen omentum-derived ACM from
five EAC patients for soluble adhesion molecules and ICAM-1
and L-selectin were shown to be most abundant, indicative
of the adhesive properties of the omental microenvironment
(Figure 1C). Secreted fractalkine levels were significantly higher
in omentum compared to matched serum regardless of patient
obesity status and interestingly, there were significantly higher
levels of soluble fractalkine in the omentum of EAC patients
with elevated serum CRP, i.e., >5 mg/l compared to those with
lower serum CRP, i.e., <5 mg/l (mean: 65.8 versus 13.87 ng/ml,
p < 0.05) (Figure 1D; Table 2). Furthermore, our data show
significant levels of T cell migration to ACM in both non-cancer
and EAC patients, irrespective of obesity status (Figure 1E).

Assessing Integrin and Adhesion Molecule
Expression Together With Memory
Phenotype of CD8+ T Cells Following
Fractalkine Treatment

To examine the effects of fractalkine on CX3CR1 expression by
CD8+ T cells, PBMC from six EAC patients were treated with
M199 media alone or M199 media supplemented with 30 ng/ml
of recombinant fractalkine for 24 h and subsequently analyzed
for VLA-4, LFA-1, alpha4 integrin, beta7 integrin, ICAM-1,
L-selectin, CD45RA, and CD27 surface expression using flow
cytometry, as described above.

Low Frequencies of CX3CR1+ CD8+
T Cells in the Omentum of EAC Patients
Are due to Significantly Diminished
Frequencies of Both the CX3CR1INT and
CX3CR1HI Subsets of CD8+ T Cells

The frequencies of CD4+ and CD8+ T cells expressing the
chemokine receptor CX3CR1 were examined in the blood and
omentum of a total of 24 EAC patients by flow cytometry. Our
results identified significantly higher frequencies of CX3CR1+
CD8+ T cells in the circulation compared to their CD8+ counterparts in omentum (blood versus omentum mean: 48.87 versus
23.64%, p = 0.0002, Figure 2A) and compared to proportions of

Statistical Analyses

Statistical analysis was carried out using Prism GraphPad Version
5.0. Differences between groups were assessed using two-tailed
paired, Wilcoxon sign-rank test, unpaired non-parametric
Mann–Whitney U tests, and one-way ANOVA with Tukey post hoc
analysis where appropriate. Significant associations between
fractalkine, CX3CR1, and clinical parameters were investigated
using Spearman’s rank-order correlation test. p Values of <0.05
were considered to be significant.

TABLE 2 | Correlations of CX3CL1 levels and frequencies of CX3CR1NEG
expressing T cells with waist circumference, visceral fat area (VFA), and body
mass index.

RESULTS

R2 values for correlations of
CX3CR1 and the following
measurements

Significantly High Levels of Soluble
Fractalkine in the Omentum of EAC
Patients Can Drive Migration of EAC
Patient-Derived T Cells

Serum CX3CL1
Omental CX3CL1
Peripheral CX3CR1+ CD4+ T cells
Omental CX3CR1+ CD4+ T cells
Peripheral CX3CR1+ CD8+ T cells
Omental CX3CR1+ CD8+ T cells

Secreted fractalkine was quantified by MSD V-Plex ELISA in the
matched serum and omental adipose tissue conditioned media
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Waist
circumference
R2 value
0.028
0.003
−0.15
0.193
−0.298
0.464

VFA
R2 value

Body mass
index
R2 value

0.058
0.126
0.008
0.159
−0.216
0.044

0.119
0.134
−0.054
0.036074
−0.164
0.073
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FIGURE 2 | Frequencies of CX3CR1+ CD8+ T cells are significantly lower in omentum of esophagogastric adenocarcinoma (EAC) patients compared to frequencies
of both peripheral blood CX3CR1+ CD8+ T cells and CX3CR1+ CD4+ T cells. Peripheral blood mononuclear cells and stromal vascular fraction of omentum were
isolated from EAC patients. (A) Scatterplots show the frequencies of CX3CR1+ CD8+ and CD4+ T cells in the blood and omentum of a total of 24 EAC patients.
(B) Representative dot plots of CX3CR1+ CD8+ and CX3CR1+ CD4+ T cells (gated on and shown as a percentage of total CD3+ population) in blood and omentum.
(C) Bar chart showing the frequencies of CD8+ cells expressing no CX3CR1 (CX3CR1NEG), intermediate (CX3CR1INT), and high levels of CX3CR1 (CX3CR1HI) in the
blood (white) and omentum (black) of 24 EAC patients. (D) Representative dot plot of circulating CD8+ T cells expressing no CX3CR1 (CX3CR1NEG), intermediate
levels of CX3CR1 (CX3CR1INT), and high levels of CX3CR1 (CX3CR1HI). (E) Bar charts showing the CX3CR1+ CD8+ and CD4+ T cells in the blood and omentum of 8
non-cancer control subjects and 24 EAC patients (left) and 14 non-obese and 10 obese EAC patients (right). *p < 0.05, *p < 0.01, ***p < 0.001 by paired and
unpaired t tests.
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circulating CX3CR1+ CD4+ T cells (mean: 14.48%, p < 0.0001,
Figure 2A). These differences were paralleled by substantially but
not significantly higher frequencies of CX3CR1+ CD4+ T cells
in EAC omentum (mean: 30.76%, Figures 2A,B) compared to
blood. Further analysis revealed that the diminished numbers
of CX3CR1+ CD8+ T cells within the omentum were due to
significantly lower frequencies of CD8+ T cells expressing both
intermediate and high levels of CX3CR1 and significantly higher
frequencies of CX3CR1NEG populations in omentum, compared to
blood (blood versus omentum mean of CX3CR1NEG: 60.24 versus
81.03%, p < 0.01, CX3CR1INT: 36.34 versus 18.25%, p < 0.01,
CX3CR1HI: 3.41 versus 0.72%, p < 0.05, Figure 2C). The highest
proportions of circulating CX3CR1+ cells were identified within
the CX3CR1INT CD8+ T cell population (Figures 2C,D). While
such observations in CX3CR1 expression by T cells were consistent
among obese and non-obese EAC patients, there were significantly
higher frequencies of CX3CR1+ CD8+ T cells in the circulation
of non-cancer controls, compared to EAC patients (non-cancer
versus EAC: 70.33 versus 48.87%, p < 0.05, Figure 2E; Table 2).

CX3CR1+ CD8+ T cells convert to CX3CR1NEG CD8+ T cells
upon encountering their ligand, which is secreted in abundance
in the omental microenvironment. Blood-derived T cells from
17 EAC patients were treated with M199 media or recombinant
fractalkine for 2 h to simulate the effects of the high fractalkine
levels in the omental microenvironment. Flow cytometric analysis revealed that surface expression of CX3CR1 was significantly
decreased on peripheral blood CD8+ but not CD4+ T cells or
omental CD8+ T cells following 2 h treatment with recombinant
fractalkine (untreated versus treated CD8+ T cells: 52.2 versus
4.238, p = 0.0001, Figures 3A,B). Further analysis revealed that
CX3CR1 expression by peripheral blood CD8+ T cells is reduced
between 15 and 30 min post-treatment with most significant
reductions observed at 2 and 24 h post-treatment (Figure 3C,
p < 0.001). Fractalkine treatments performed at a temperature
of 4°C or in combination with treatment of 80 µM dynasore, a
GTPase inhibitor, demonstrated significantly reduced efficacy to
decrease CX3CR1 expression on CD8+ T cells thus confirming
that the observed reductions were due to endocytosis (Figure 4A).

CX3CR1 Expression by Peripheral Blood
but Not Omental CD8+ T Cells Is
Significantly Diminished Following
Treatment With Recombinant Fractalkine

CX3CR1 Internalization by CD8+ T Cells Is
Sustained Following Treatment With
Recombinant Fractalkine and the
Receptor Is Not Degraded or Recycled to
the Cell Surface

To ascertain why enrichments of CX3CR1+ CD4+ T cells were
detected in the omentum, while highest frequencies of CX3CR1+
CD8+ T cells were detected in the circulation, we assessed whether

Surface expression of CX3CR1 by CD8+ T cells was not restored
when 2 h treatment with fractalkine was followed by culture

FIGURE 3 | Peripheral blood CD8+ T cells exhibit a significant and sustained reduction in CX3CR1 surface expression following treatment with recombinant
fractalkine. (A) Frequencies of CX3CR1+ cells, as a percentage of CD8+ T cells (left) and CD4+ T cells (right) following; treatment with M199 media alone (NT) or
30 ng/ml of recombinant fractalkine for 2 h (n = 17); (B) representative dot plots of CX3CR1 expression following treatment with M199 media alone (NT) or 30 ng/ml
of recombinant fractalkine for 2 h. (C) Frequencies of CX3CR1+ cells, as a percentage of CD8+ T cells following treatment with M199 media alone (NT) or 30 ng/ml
of recombinant fractalkine across a time course of 15 min, 30 min, 1 h, 2 h, or 24 h (n = 4). ***p < 0.001 by paired t tests.
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FIGURE 4 | Continued
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FIGURE 4 | CX3CR1 is endocytosed following fractalkine treatment and is not subsequently recycled to the surface of CD8+ T cells or secreted but, intracellular
accumulations of the protein are detectable. (A) Frequencies of CX3CR1+ cells, as a percentage of CD8+ T cells following treatment with M199 media alone (NT),
30 ng/ml recombinant fractalkine alone (treatment alone), 30 ng/ml recombinant fractalkine at 4°C and 30 ng/ml recombinant fractalkine plus 80 µM Dynasore
(n = 10). (B) Bar chart showing frequencies of CX3CR1+ cells, as a percentage of CD8+ T cells following treatment with M199 media alone (NT) or 30 ng/ml of
recombinant fractalkine for 24 h (fractalkine, light gray dot pattern) followed by removal from a fractalkine-free environment for 24 h (fractalkine, dark gray no
pattern) or 48 h (fractalkine, light gray no pattern) (n = 6). (C) Bar chart showing frequencies of CX3CR1+ cells, as a percentage of CD8+ T cells following
treatment with M199 media alone (NT) or 30 ng/ml of recombinant fractalkine for 24 h (fractalkine, light gray dot pattern) followed by removal from a fractalkinefree environment for 24 h and treatment with 50 ng/ml of TNF-α, 100 ng/ml of IFN-γ, IL-17, IL-6, IL-7, IL-15, IL-18, IL-36, and 50 U/ml of IL-2 (n = 3). (D) Western
Blot (left) showing CX3CR1 and beta-actin protein in peripheral blood-derived CD8+ T cells from three donors following 24 h of no treatment (N1, N2, and N3) or
fractalkine treatment (F1, F2, and F3) and densitometry data (right) from this western blot displayed as fold change bar chart. (E) Soluble CX3CR1 levels in the
supernatant of peripheral blood mononuclear cells treated with M199 alone or fractalkine for 24 or 48 h (n = 3). *p < 0.05, **p < 0.01 by paired t-test.

in fractalkine-free media for 24 and 48 h, suggesting that the
receptor is not recycled to the surface following endocytosis
(Figure 4B). Stimulation with 50 ng/ml of TNF-α or 100 ng/ml
of IFN-γ, IL-6, IL-7, IL-17, IL-18, IL-15, or IL-36 or 50 U/ml
of IL-2 for 24 h following removal of fractalkine, did not
induce recycling of CX3CR1 to the surface of CD8+ T cells
(Figure 4C). Western blot revealed that there are consistent
accumulations of CX3CR1 protein levels in CD8+ T cells
following 24 h fractalkine treatment compared to untreated
CD8+ T cells demonstrating that the receptor is not degraded
following fractalkine-mediated endocytosis (Figure 4D).
Furthermore, ELISA revealed that the levels of CX3CR1 shed
by T cells are not increased following 24 or 48 h of fractalkine
treatment (Figure 4E).

ICAM-1 on circulating CX3CR1NEG and CX3CR1INT CD8+
T cells (5). Our data revealed significantly lower frequencies
of ICAM-1+ and L-selectin+ cells within the CX3CR1INT CD8+
T cell population compared to their CX3CR1NEG counterparts,
indicating differential migratory and adhesive properties of
these subsets (CX3CR1NEG versus CX3CR1INT ICAM-1: 68.4
versus 47.1%, p = 0.02, L-selectin: 60.4 versus 35.4%, p = 0.02,
Figure 5C).

Increased L-Selectin Surface Expression
Follows Fractalkine-Mediated CX3CR1
Endocytosis on CD8+ T Cells

To simulate the high fractalkine levels in the omental microenvironment and examine whether this affects adhesion molecule
expression and memory phenotype; fractalkine treatment of
peripheral blood T cells from three donors was performed for
24 h. Fractalkine treatment induced a significant increase in surface expression of L-selectin but not ICAM-1 on CD8+ T cells
following 24 h, indicating that it alters their adhesiveness and
lymphoid tissue homing capacity (L-selectin: 24.6 versus 35.5%,
p < 0.05, Figure 6A). Fractalkine treatment had no significant
effects on ICAM-1, LFA-1, VLA-4, or integrin alpha4 and beta7
surface expression or memory phenotype of CD8+ T cells
defined by CD45RA and CD27 expression (Figures 6B–D). In
data not shown, 24 h fractalkine treatment had no significant
effects on pro-inflammatory cytokine production by the CD8+
T cells.

CX3CR1NEG and CX3CR1INT Populations of
CD8+ T Cells in the Peripheral Blood Have
Significantly Different Memory Phenotype
and Adhesion Molecule Expression

Since the CX3CR1+ compartments of CD8+ T cells were
predominantly CX3CR1INT and this subpopulation has been
shown to have the potential to convert to CX3CR1NEG CD8+
T cells, we focused our phenotypical comparisons between this
subset and the CX3CR1NEG CD8+ T cell subset [Figure 2C; (5)].
Significant differences in memory phenotype were identified
between the CX3CR1NEG and CX3CR1INT CD8+ T cells based
on their CD45RA and CD27 surface expression using the Dieli
scheme; terminally differentiated (CD45RA+CD27−), naive
(CD45RA+CD27+), effector memory (CD45RA−CD27−), and
central memory (CD45RA−CD27+) (26). Our data revealed that
circulating CX3CR1INT CD8+ T cells were significantly different
to CX3CR1NEG CD8+ T cells in memory phenotype; CX3CR1INT
CD8+ T cells were predominantly central memory and effector
memory phenotype while CX3CR1NEG CD8+ T cells contained
more naive and terminally differentiated cells (Figure 5A,
central memory: p = 0.0001, effector memory: p < 0.05,
naive: p = 0.001, terminally differentiated: p = 0.002). These
phenotypical differences were attributable to significantly lower
CD45RA surface expression and significantly higher CD27 surface expression within the CX3CR1INT CD8+ T cell population
(CX3CR1INT versus CX3CR1NEG CD45RA: 27.2 versus 96.4%,
p < 0.001, CD27, 94.9 versus 68.8%, p < 0.05, Figure 5B). To
elucidate whether our data compared to previous reports of
lower L-selectin surface expression within CX3CR1INT T cell
population, we examined the expression of L-selectin and
Frontiers in Immunology | www.frontiersin.org

DISCUSSION
High Levels of Soluble Fractalkine in
Omentum Can Drive T Cell Migration and
May Represent a Hallmark of MetaInflammation in Obesity-Associated
Cancer Patients

For the first time, this study has revealed significantly high
levels of soluble fractalkine in the omental adipose tissue
conditioned media (ACM) derived from patients with the
obesity-associated cancer EAC. This is in line with previous
observations of fractalkine enrichment in VAT (8). Known
inducers of fractalkine include the inflammatory cytokines
IFN-γ, TNF-α, and IL-1β (13). Such an abundance of fractalkine
was unsurprising as we have reported enrichments of IFN-γ
and TNF-α producing T cells together with secreted IL-1β in
9
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FIGURE 5 | CX3CR1NEG and CX3CR1INT populations represent significantly different CD8+ T cells in the peripheral blood with significantly different memory
phenotypes, L-selectin, and ICAM-1 expression. (A) Bar charts showing the frequencies of naive, central memory, effector memory, and terminally differentiated
CD8+ T cells, characterized by CD45RA and CD27 expression within the CX3CR1NEG and CX3CR1INT populations in peripheral blood of six non-cancer controls. (B)
Bar chart showing frequencies of peripheral blood-derived CD8+ T cells expressing CD45RA (top) and CD27 (bottom) within CX3CR1NEG and CX3CR1INT populations
(n = 3). (C) Bar chart showing frequencies of peripheral blood-derived CD8+ T cells ICAM-1 and L-selectin within CX3CR1NEG and CX3CR1INT populations (n = 3).
p < 0.05, **p < 0.01, ***p < 0.001 by unpaired t tests.

the omentum of EAC patients (13, 22, 23). Interestingly, significantly higher fractalkine levels were observed in the patients
with highest serum CRP levels, which is indicative of its role in
meta-inflammation and in line with previous reports of the circulating levels of CRP and fractalkine in metabolic dysfunction
(7, 27). However, this is the first reported association of high
fractalkine in the omentum and high serum CRP in obesityassociated cancer. Soluble fractalkine levels were significantly
high in both obese and non-obese omentum in both cancer
and non-cancer subjects. Furthermore, soluble cues from both
obese and non-obese and both cancer and non-cancer omental
microenvironments drove T cell migration suggesting that this
tissue is a rich source of this chemokine and recruits significant

Frontiers in Immunology | www.frontiersin.org

numbers of T cells, regardless of obesity status. Interestingly,
while fractalkine was secreted in abundance in the omentum
and could drive in vitro EAC-derived T cell migration, this
was not paralleled by high frequencies of T cells expressing
its specific receptor in this tissue. In fact, the highest proportions of CX3CR1INT cells were identified in circulating CD8+
T cell populations and not the omentum. Such frequencies
were still significantly lower than CD8+ T cell frequencies in
non-cancer controls suggesting that the fractalkine:CX3CR1
axis might be perturbed by malignancy in this study cohort.
Together with our previously reported data, our investigations
suggest that fractalkine together with MIP-1α in the omentum
recruit inflammatory T cells to this tissue in EAC, most likely

10

August 2018 | Volume 9 | Article 1867

Conroy et al.

Fractalkine-Mediated Regulation of CX3CR1

FIGURE 6 | The fractalkine-mediated CX3CR1INT to CX3CR1NEG conversion of CD8+ T cells is followed by enhanced L-selectin expression. (A) Bar charts showing
frequencies of peripheral blood-derived CD8+ T cells expressing L-selectin (top) and ICAM-1 (bottom) following treatment with M199 media alone (untreated, black)
or 30 ng/ml of recombinant fractalkine for 24 h (fractalkine, white pattern) (n = 6). (B) Bar chart (top) showing frequencies of peripheral blood-derived CD8+ T cells
expressing alpha4 and beta7 integrins following treatment with M199 media alone (untreated, black) or 30 ng/ml of recombinant fractalkine for 24 h (fractalkine,
white pattern) (n = 6). (B) Bar chart (bottom) showing frequencies of peripheral blood-derived CD8+ T cells expressing LFA-1 and VLA-4 following treatment with
M199 media alone (untreated, black) or 30 ng/ml of recombinant fractalkine for 24 h (fractalkine, white pattern) (n = 6). (C) Bar chart showing the frequencies of total
CD45RA+ and CD27+ populations of CD8+ T cells following treatment with M199 media alone (untreated, black) or 30 ng/ml of recombinant fractalkine for 24 h
(fractalkine, white pattern) (n = 6). (D) Bar chart showing the frequencies of naive, effector memory, central memory, and terminally differentiated CD8+ T cells,
characterized by CD45RA and CD27 expression following treatment with M199 media alone (untreated, black) or 30 ng/ml of recombinant fractalkine for 24 h
(fractalkine, white pattern) (n = 6). *p < 0.05 by paired t tests.
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Fractalkine Mediates CX3CR1INT to
CX3CR1NEG Conversion in Peripheral
Blood-Derived CD8+ T Cells via Receptor
Endocytosis

contributing to the pathological adipose tissue inflammation
at the expense of effective anti-tumor immunity (19). As other
studies have shown that fractalkine serves distinctive roles in
different inflammatory diseases such as diabetes, dermatitis,
asthma, and neuropathic pain, we propose that it may also
serve functions additional to T cell chemotaxis in the omentum
of EAC patients (8, 11, 12, 28).

CX3CR1 has recently been identified as a marker of CD8+ T cell
memory during viral infection in murine models but the role if
any of fractalkine in the differentiation of such T cells has not
been described (5). Here, a significant decrease in CX3CR1
surface expression following fractalkine treatment was observed
in the CD8+ T cell compartment in the peripheral blood but not
in the T cell populations containing lower levels of CX3CR1
expression; circulating CD4+ T cells or omental CD4+ or CD8+
T cells. Such cell type- and compartment-specific cell surface
regulation of a chemokine receptor is not unique to CX3CR1 and
similar findings have been reported with CXCR4 (31). Indeed,
the internalization of CXCR4 facilitated its association with the
T cell receptor and enhanced co-stimulation of cytokine production by T cells thus emphasizing the multifaceted functions of
chemokines in immunity (3). Further work performed in this
study has revealed that the reduction in CX3CR1 expression is
due to endocytosis in line with previous reports on macrophages
in sepsis patients (32). To our knowledge, this is the first report
of CX3CR1 endocytosis on CD8+ T cells following ligand binding and implicates fractalkine as master regulator of CX3CR1INT
to CX3CR1NEG conversion. Such endocytosis is not followed by
CX3CR1 recycling to surface within 48 h of ligand binding even
when fractalkine is removed. Furthermore, fractalkine-mediated
endocytosis of its receptor does not lead to increased levels of
CX3CR1 shedding. In fact, our western blot data show that the
protein accumulates within the cell and stimulation with an
array of inflammatory cytokines simulating the soluble cues of
an inflammatory microenvironment could not trigger its recycling to the cell surface. These data suggest that fractalkine elicits
significant and long-lasting changes in CD8+ T cells, which may
culminate in their retention in the omentum.

Diminished Frequencies of CX3CR1+
CD8+ T Cells and Increased Frequencies
of CX3CR1NEG CD8+ T Cells in Omentum
Are Indicative of Fractalkine-Mediated
CX3CR1INT to CX3CR1NEG Conversion

Our data reveal significantly higher proportions of CX3CR1HI
and CX3CR1INT CD8+ T cells in the peripheral blood of EAC
patients and significantly diminished frequencies in the
omentum. CX3CR1HI and CX3CR1INT CD8+ T cells represent
two of three distinct memory CD8+ T cell subsets which have
recently been defined by their CX3CR1 expression (5). This
classification includes a central memory CX3CR1NEG population that expresses higher levels of L-selectin and is more
prevalent in the lymphoid tissue, a CX3CR1INT population that
expresses lower levels of L-selectin and circulates between the
peripheral tissue and the blood, and a CX3CR1HI population
that lacks L-selectin and the migratory capacity of the other
populations and is predominantly effector memory/terminally
differentiated in phenotype (5). CX3CR1INT CD8+ T cells have
been described as peripheral memory T cells (5). They undergo
more homeostatic divisions than any other memory subset to
maintain self-renewal and can also convert to CX3CR1NEG to
feed the central memory pool of CD8+ T cells (5). However,
the trigger or mediators for such transition have not been
previously identified. To date, few studies have looked at the
tissue localization of CX3CR1+ CD8+ T cell populations with
recent reports of their migration to lymph nodes, spleen, bone
marrow, lung, and liver in murine models of viral infection (5,
29). Here, treatment of peripheral blood CD8+ T cells with the
CX3CR1 ligand fractalkine resulted in significant reduction
in their CX3CR1 surface expression and thus expanded the
CX3CR1NEG pool of CD8+ T cells. Due to the abundance of
fractalkine in the omentum and due to previous reports that
CX3CR1INT CD8+ T cells can replenish the CX3CR1NEG CD8+
T cell pool, we propose that fractalkine recruits circulating
T cells to omentum and subsequently mediates the conversion
from CX3CR1INT CD8+ T cells to CX3CR1NEG CD8+ T cells, thus
implicating the omentum as a key site in the accumulation of the
memory CD8+ T cell pool in EAC and potentially other conditions. While CX3CR1 is the specific receptor for fractalkine, it
must be noted that Eotaxin-3 (CCL26) has been identified as
a functional chemoattractant for CX3CR1+ CD8+ T cells (30).
However, our data have revealed that EAC omentum is not an
abundant source of Eotaxin-3 (data not shown), compared to
chemokines such as MIP-1α and fractalkine thus reducing the
likelihood of this chemokine governing CX3CR1+ CD8+ T cell
trafficking to omentum in EAC.

Frontiers in Immunology | www.frontiersin.org

Enhanced L-Selectin Expression by
Peripheral Blood-Derived CD8+ T Cells
Following Fractalkine-Mediated
Conversion From a CX3CR1INT to a
CX3CR1NEG Phenotype

An abundance of soluble ICAM-1 and L-selectin levels were
detected in the omentum-derived ACM of EAC patients, suggesting their shedding by cells in this inflamed tissue and may
be indicative of their role in immune cell arrest and retention
in the VAT. Significant higher frequencies of ICAM-1+ and
L-selectin+ cells within the CX3CR1NEG CD8+ T cell population
are also reported here. Since CX3CR1NEG CD8+ T cells are the
predominant subset within the omentum, our data suggest that
such cells have altered adhesive and migratory properties and
this may serve a function in retention within the omentum.
Interestingly, our data also revealed significantly different
memory phenotypes between the peripheral blood CX3CR1NEG
and CX3CR1INT CD8+ T cell subsets and such characteristics
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have been previously described together with differences in their
migratory properties and those of CX3CR1HI CD8+ T cells (5).
Others have shown that CX3CR1INT CD8+ T cells in mice can
increase their L-selectin expression and convert to CX3CR1NEG
CD8+ T cells, unlike CX3CR1HI CD8+ T cells (5). For the first
time, we identify fractalkine as a mediator of increased L-selectin
expression by peripheral blood CD8+ T cells following their fractalkine-mediated conversion from a CX3CR1INT to CX3CR1NEG
phenotype and we propose that these sequenced alterations occur
in the fractalkine-rich environment of the omentum changing
the migratory properties of CD8+ T cells in EAC. While soluble
fractalkine induces changes in L-selectin surface expression, that
of ICAM-1, VLA-4, LFA-1, alpha-4, and beta-integrin together
with memory phenotype are unchanged. Contrary to ICAM-1
expression being highest within the CX3CR1NEG CD8+ T cell
population in blood, these data reveal that fractalkine-mediated
conversion of CX3CR1INT to CX3CR1NEG CD8+ T cells is not
accompanied by an increase in ICAM-1 expression and this event
may be mediated by another soluble factor. These data identify
a novel role for fractalkine in the alteration of migratory and
lymphoid tissue homing capacity of CD8+ T cells and align with
previous reports of fractalkine and CX3CR1 regulating immune
cell responses via distinct disease-dependent mechanisms (28,
32). For instance, this chemokine axis promotes T cell survival in
asthma, while it promotes T cell retention in inflamed skin in dermatitis and plays a role in immune paralysis in sepsis (11, 28, 32).
However, for the first time, this study identifies fractalkine as a
player in T cell recruitment to omentum and a master regulator of
CX3CR1 expression, CX3CR1INT to CX3CR1NEG conversion and
L-selectin expression. Together with our previously published
data, we propose that such alterations change the fate of CD8+
T cell trafficking and CD8+ T cell-mediated immunity in EAC
and may lead to their retention in the fractalkine-rich omentum
where they contribute to pathological inflammation to the detriment of effective anti-tumor immunity.

selective bias for cytotoxic lymphocytes such as CD8+ T cells and
NK cells, the preferential migration of CD8+ T cells to omentum
over tumor might be detrimental for anti-tumor immunity in
EAC and other obesity-associated cancers (33). Antagonizing
the CX3CR1:fractalkine pathway might attenuate CD8+ T cellmediated inflammation in the omentum but secondary to this it
might prevent the CX3CR1INT to CX3CR1NEG conversion and disrupt frequencies and migration of peripheral and central memory
CD8+ T cells, which would also be detrimental to anti-tumor
immunity. Therefore, our findings place fractalkine as more than
a chemotactic cytokine driving T cell-mediated inflammation in
EAC. Further in vivo work will be necessary to elucidate the consequences of blocking this pathway in obesity-associated cancer.
These novel data advance our knowledge on the multifaceted
functionality of fractalkine and may inform T cell therapies and
chemokine-targeted therapies in the future.
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